Mannose-Binding Lectin Gene Variation and Cardiovascular Disease in Canadian Inuit (Technical Briefs) Mannose-Binding Lectin Gene Variation and Cardiovascular Disease in Canadian Inuit (Technical Briefs)

Mannose-Binding Lectin Gene Variation and Cardiovascular Disease in Canadian Inuit (Technical Briefs‪)‬

Clinical Chemistry 1999, August, 45, 8

    • 79,00 Kč
    • 79,00 Kč

Publisher Description

Canadian Inuit have an age-adjusted mortality from cardiovascular disease that is ~40% lower than the rest of Canada (1). This might result from the protective influence of certain environmental factors, such as the consumption of Arctic fish (1) or of certain genetic factors. For example, the thermolabile variant of the MTHFR gene, which encodes methylenetetrahydrofolate reductase, is one-sixth as prevalent in Inuit than in subjects of European origin (2). However, there are some inconsistent genetic findings in these people. For example, genetic variants that are associated with an increased risk of cardiovascular disease, such as the E4 allele of the APOE gene and the T235 allele of the AGT gene, are significantly more prevalent in Inuit than in whites (3). The resolution of such inconsistencies may come from the fact that several genes likely determine susceptibility to cardiovascular disease (4). It will thus be necessary to evaluate newer genetic determinants of cardiovascular disease risk in the Inuit. One possible new genetic determinant for cardiovascular risk is the common coding sequence variation in the MBL gene, which encodes mannose-binding lectin (MBL) (5). MBL is an innate immune defense protein that binds mannose and other sugars on the surface of a variety of infectious agents, thereby facilitating phagocytosis and activation of the complement cascade (6, 7). MBL likely modulates the severity of infection with Chlamydia pneumoniae (6, 7), a pathogen linked by several lines of experimentation to the initiation and propagation of atherosclerosis (8). This might explain the association of genetic variation in MBL with severe atherosclerosis (5).

GENRE
Science & Nature
RELEASED
1999
1 August
LANGUAGE
EN
English
LENGTH
9
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SIZE
175.7
KB

More Books by Clinical Chemistry

Bioinformatics Methods for Prioritizing Serum Biomarker Candidates (Abstract of Oak Ridge Posters) Bioinformatics Methods for Prioritizing Serum Biomarker Candidates (Abstract of Oak Ridge Posters)
2006
D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report) D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report)
2004
Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs) Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs)
2005
Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs) Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs)
2005
Newborn Screening for Lysosomal Storage Disorders (Editorials) Newborn Screening for Lysosomal Storage Disorders (Editorials)
2005